Skip links


Aligning Business Needs, Maximizing Digital Potential

Jeffrey Fleischman played a significant role in the Digital CXO article titled “Diageo Partners with SAP and IBM on Digital Transformation.” The article highlights the recent announcement by beverage company Diageo regarding its ambitious five-year business transformation plan, which involves a substantial investment in technology and services. The primary objectives of this initiative are to gain valuable insights, make informed decisions quickly, enhance business resilience, elevate customer service, and effectively adapt to changing consumer trends.

Jeff shared insights from Altimetrik’s digital business methodology, emphasizing common concerns that hinder companies from pursuing digital transformation. These concerns include worries about costs, disruptions to the business, and a lack of the necessary skills and tools to accelerate digital capabilities. Companies often seek partnerships to address challenges such as the absence of a single source of truth (SSOT), a business-led approach that focuses on outcomes, a cloud-based digital business platform (DBP) to manage their technology stack, the adoption of an agile digital culture, or the need for specific skills internally.

Jeff emphasized the importance of aligning digitalization efforts with the business needs and utilizing data and technology to achieve them. He also stressed the significance of measuring progress by achieving specific milestones within expected timeframes and continuously monitoring end-to-end performance to ensure compliance with quality and traceability standards.

Read the full News >


Latest News

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes